Entera Bio Ltd.
About Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $42.0K
- Net income
- -$11.4M
- Total assets
- $16.0M
- Market cap
- $58.2M
- Gross margin
- 0.0%
- Operating margin
- -27450.0%
- Net margin
- -27235.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $42.0K
- Cost of revenue
- $42.0K
- Gross profit
- $0
- Operating expenses
- $11.5M
- Operating income
- -$11.5M
- Income tax
- $0
- Net income
- -$11.4M
- EPS (basic)
- $0.25
- EPS (diluted)
- $0.25
Balance sheet
- Total assets
- $16.0M
- Current assets
- $15.3M
- Total liabilities
- $2.9M
- Current liabilities
- $2.2M
- Shareholders’ equity
- $13.1M
Cash flow
- Operating cash flow
- -$7.4M
- Investing cash flow
- -$107.0K
- Financing cash flow
- $13.7M
- Net cash flow
- $6.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $58.2M
- P/E ratio
- 4.8
- EPS (diluted)
- $0.25
- Shares outstanding
- 48.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 28, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $11.4M in FY2025.
- Revenue declined 93% from FY2021 to FY2025.
- Gross margin of 0.0%, net margin -27235.7%.
- Trading 62% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 4.8.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Entera Bio Ltd..
Write a review
News about Entera Bio Ltd.
News & sentiment via Polygon.io
